Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide versus Ozempic for weight loss: the facts behind the confusion
You've searched "semaglutide vs Ozempic", here's what's really going on
Picture the scene: someone in your office mentions they're on Ozempic and losing weight. You search it, find the price is surprisingly high and the waiting list even higher, then stumble across articles about "semaglutide" as if it were a separate, possibly cheaper option. It isn't. Semaglutide is the generic chemical name; Ozempic and Wegovy are both brand names for the same molecule, made by Novo Nordisk. The difference lies entirely in their UK licensing and dosing.
Ozempic (0.5mg, 1mg, 2mg) is licensed by the MHRA for glycaemic control in adults with type 2 diabetes. Wegovy (0.25mg up to 2.4mg, with a 7.2mg strength now also approved) is licensed for chronic weight management in adults with a qualifying BMI. Both are prescription-only medicines, you cannot legally obtain either without a valid prescription following clinical assessment, and the distinction between them matters practically because a prescriber cannot lawfully issue a weight-loss prescription for Ozempic under its current UK authorisation.
The MHRA has been explicit: GLP-1 medicines are prescription-only and must not be used without clinical oversight. Using Ozempic for weight loss off-label, particularly through unverified sellers, is one of the routes the MHRA has specifically flagged as a risk, including the risk of counterfeit pens. That's the shape of the confusion, and it's worth clearing up before anything else.
What's actually licensed for weight loss in the UK, and how they compare
Once you set Ozempic aside as a weight-loss option, the realistic comparison for someone interested in semaglutide is what Wegovy offers versus the alternatives. The table below sets out the key facts.
| Feature | Ozempic (semaglutide) | Wegovy (semaglutide) |
|---|---|---|
| UK licence | Type 2 diabetes only | Weight management (BMI ≥30, or ≥27 with a weight-related condition) |
| Maintenance dose | Up to 2mg | 2.4mg standard; 7.2mg pen also approved (April 2026) |
| Prescribable for weight loss? | No (off-label; not standard UK practice) | Yes, if clinically suitable |
| Trial evidence for weight loss | Not the primary indication; evidence base is glycaemic | STEP 1 trial: ~15% average body-weight reduction over 68 weeks at 2.4mg [NEJM STEP 1] |
| NICE recommendation | Not recommended for weight loss | TA875: recommended within specialist weight management services, maximum 2 years [NICE TA875] |
| Private prescription route | Not offered by regulated weight-loss services for this purpose | Available via GPhC-registered online pharmacies following clinical review |
Wegovy's 7.2mg single-dose pen, approved by the MHRA in April 2026, pushed the average weight-loss figure in trials to around 20.7% over 72 weeks, closing ground on tirzepatide results. For anyone comparing semaglutide options for weight loss, Wegovy is the medicine; Ozempic is simply not in that conversation under UK licensing.
How Wegovy sits alongside other licensed options, and what a prescriber considers
Wegovy isn't the only licensed weight-loss injection in the UK. Some patients arrive at us confused about Wegovy versus Ozempic specifically, but others are weighing up semaglutide against tirzepatide (Mounjaro), which works on two receptors rather than one. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity. That gap narrows at Wegovy's 7.2mg dose. Neither result tells you which medicine suits your physiology, your other medications, or your medical history.
For patients weighing up their injection options more broadly, the choice is genuinely clinical. A prescriber considers existing conditions, previous treatment history, and tolerance. Dose titration (the gradual step-up that both Wegovy and Mounjaro follow) also plays a part in who settles well on which medicine. At nume, that assessment is done by a named GPhC-registered Independent Prescriber reading your consultation the same day. The clinical team page gives a sense of who that involves.
If needles are a concern, the oral semaglutide tablet (Wegovy tablets, approved in the UK in June 2026 as the first oral GLP-1 for weight management) is now also available. Worth knowing that option exists before assuming an injection is the only route.
Where to go from here if Wegovy is what you're actually looking for
Ozempic won't be prescribed to you for weight loss by a legitimate UK prescriber, and if a seller online is offering it for that purpose without proper clinical assessment, that is itself a warning sign. The MHRA's counterfeit enforcement throughout 2025 and 2026 has consistently found fake pens sold through channels that bypass clinical checks: around 20 million doses of illegally traded weight-loss medicines were seized, with a street value of approximately £45 million. The route that's safe is the licensed one.
If you're looking for semaglutide for weight loss, Wegovy is the product to ask about. A consultation through a GPhC-registered pharmacy (verified at the GPhC register) means a prescriber reviews your history before a pen is dispensed. At nume, once that review is complete and treatment is approved, it ships the same day and arrives in a DPD-tracked parcel the next working day, in plain packaging with no indication of what's inside. The prescriber's decision is what matters most. Start your free consultation and let them take it from there.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.